News

Huntexil Failed to Improve Motor Function of Huntington’s Patients in Phase 2 Trial

Although well-tolerated, the investigational treatment Huntexil (pridopidine) failed to improve motor functions in a year-long Phase 2 clinical trial of Huntington’s patients. The research, “Safety and efficacy of pridopidine in patients with Huntington’s disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study,” appeared in…

Rising Healthcare Costs Strain EU Budgets Even as New Therapies Flourish

Cash-strapped governments across the 28-member European Union are struggling to control runaway healthcare expenditures — at exactly the same time as the promise of new but expensive therapies to treat rare diseases has never been greater. That’s the paradox faced by pharmaceutical companies as well as patient advocacy groups in…

Gait, Balance Problems Can Help Diagnose Late-Onset Huntington’s, Study Finds

Late-onset Huntington’s disease (emerging at age 59 or older), progresses similarly to common-onset Huntington’s except that late-onset patients more frequently showed gait and balance problems as their first symptom, new research has found. This finding suggests that observing problems with gait and balance might be helpful in diagnosing late-onset Huntington’s disease…

Compound in Raspberries May Help Protect Against Huntington’s, Other Neurodegenerative Diseases, Study Says

A bioactive compound present in raspberries called salidroside can prevent the cellular toxicity that occurs as a consequence of protein accumulation in certain neurodegenerative diseases, including Huntington’s disease, a study reports. The study, “Identification and microbial production of the raspberry phenol salidroside that is active against Huntington’s disease,” was published…